BioMarin Pharmaceuticals Inc (BMRN)
Health Care ยท Pharmaceutical Preparations
BioMarin Pharmaceuticals Inc (BMRN) is listed on Nasdaq, where its shares have traded since July 23, 1999. SentiSense covers BioMarin Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Alexander Hardy is its chief executive officer. The company reports 3,221 employees, and its corporate website is www.biomarin.com.
About BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Latest reported results
BioMarin Pharmaceutical Inc. reported revenue of $989.7 million for Q2 FY2026, up 19.9% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 553 institutions reported holding BMRN, with 193.6 million shares worth $11.1 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Dodge & Cox. Of the 5 largest reported holders, 1 opened a new position in BMRN, 3 added shares and 1 reduced its position during the quarter.
More on BMRN
- BMRN sentiment: whether news and social coverage of BioMarin Pharmaceuticals Inc leans bullish or bearish, and the stories driving it.
- BMRN ownership: all 553 reporting institutions, plus insider and congressional trades.
- BMRN financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
SentiSense also tracks daily options readings for BioMarin Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does BioMarin Pharmaceuticals Inc do?
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases.
What sector is BMRN in?
SentiSense classifies BioMarin Pharmaceuticals Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does BMRN stock trade?
BioMarin Pharmaceuticals Inc (BMRN) is listed on Nasdaq, where its shares have traded since July 23, 1999.
Who is the CEO of BioMarin Pharmaceuticals Inc?
Alexander Hardy is the chief executive officer of BioMarin Pharmaceuticals Inc.